期刊文献+

培哚普利联合胺碘酮对阵发性心房颤动复律及复律后窦性心律维持的影响

下载PDF
导出
摘要 目的探讨胺碘酮与培哚普利联合应用对阵发性心房颤动复律及复律后窦性心律维持的影响。方法将79例阵发性心房颤动的患者随机分为2组,观察组40例采用培哚普利联合胺碘酮治疗,对照组39例仅采用胺碘酮治疗,观察2组患者用药后复律情况及复律后窦性心律维持情况。结果观察组24 h转复率为65%,给药半年后窦性心律维持率为92%,治疗后半年左心房内径值为(36.48±2.52)mm,与对照组比较无显著性差异(P>0.05);72h转复率为85%,1周转复率为97%,用药后1 a窦性心律维持率为87%,均明显高于对照组(P<0.05);治疗后1 a左心房内径为(37.05±2.66)mm,明显低于对照组(P<0.05)。结论联合应用胺碘酮及培哚普利能够显著提高阵发性心房颤动的转复率及转复后1 a窦性心律维持率,同时能够降低心房内径扩大的程度。
出处 《现代中西医结合杂志》 CAS 2013年第31期3465-3466,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献11

二级参考文献35

  • 1牛红霞,华伟,张澍.控制房颤心室率方法的研究进展[J].中国实用内科杂志,2005,25(12):1136-1137. 被引量:12
  • 2殷跃辉,刘增长,吴近近,代引,苏立,兰先彬,凌智瑜,杨小渝,罗开良.胺碘酮与氯沙坦、培哚普利联合治疗阵发性心房颤动的前瞻、随机开放研究[J].中华心血管病杂志,2006,34(4):299-302. 被引量:72
  • 3Wijjfels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation:a study in awake chronically instrumented goats[J]. Circulation, 1995,92(6) : 1954.
  • 4Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure:electrophysiological and electroanatomic mapping in humans[J].Circulation,2003,108(12) : 1461.
  • 5Goette A,Staack T, Rocken C, et al. Increased expression of extracellular signate regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation [J]. J Am Coll Cardiol,2000,35(6) :1669.
  • 6Kalus J,Coleman C, White C. The impact of suppressing the renin-angiotensin system on atrial fibrillation[J]. Clin Pharmacol, 2006,46(1) .. 21.
  • 7Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction[J]. Circulation, 1999,100 : 376.
  • 8Madrid AH,Bueno MG,Rebollo JM,et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomizedstudy[J]. Circulation,2002,106(3) :331.
  • 9Dueharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure:assessment of reduction in mortality and morbidity (CHARM) program[J]. Am Heart, 2006,152 : 86.
  • 10Mathew J P,Fontes ML,Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery [ J ]. JAMA, 2004,291 (14) : 1720 - 1729.

共引文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部